{
    "title": "114_hr639",
    "content": "The Act titled \"Improving Regulatory Transparency for New Medical Therapies Act\" amends the Federal Food, Drug, and Cosmetic Act to delay drug approval until controls under the Controlled Substances Act are issued. The Act delays drug approval until controls under the Controlled Substances Act are issued, defining the date of approval for applications and biological products. The Secretary notifies the sponsor of intent to issue a scientific evaluation and recommend controls under the Controlled Substances Act. Approval of the application is delayed until the interim final rule for the biological product is issued. The date of approval for applications and biological products is defined. The approval date of animal drugs is delayed if the Secretary intends to recommend controls under the Controlled Substances Act. Approval is contingent on the issuance of an interim final rule controlling the drug. The date of approval is defined as the later of the application approval date or the issuance of the interim final rule. The date of approval for animal drugs is delayed if the Secretary plans to recommend controls under the Controlled Substances Act. Approval is dependent on the issuance of an interim final rule controlling the drug. The date of approval for animal drugs is delayed if the Secretary intends to recommend controls under the Controlled Substances Act. Approval is contingent on the issuance of an interim final rule controlling the drug. The approval of new animal drugs may be delayed if the Secretary plans to recommend controls under the Controlled Substances Act. Approval is dependent on the issuance of an interim final rule controlling the drug. The Secretary's recommendation for controlling new animal drugs under the Controlled Substances Act can delay approval. The drug is not considered approved until an interim final rule is issued by the Attorney General. The Attorney General will issue an interim final rule controlling the drug based on recommendations from the Secretary of Health and Human Services. The rule will become immediately effective without needing to demonstrate good cause. The Attorney General will issue an interim final rule for drug control based on recommendations from the Secretary of Health and Human Services. The rule will be immediately effective without the need to demonstrate good cause. The Secretary of Health and Human Services can recommend controls under the Controlled Substances Act for drug products. If notice is provided to the sponsor within sixty days, the drug product is considered approved for commercial marketing or use under relevant provisions of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act. The Controlled Substances Act outlines conditions for commercial marketing or use of drug products, with specific dates defined as the \"covered date.\" Additionally, new drug development regulations are enhanced under the Act, requiring registration for manufacturing controlled substances for clinical trials. Section 303 of the Controlled Substances Act is amended to expedite the registration process for manufacturing controlled substances for use in clinical trials. The Attorney General must register the applicant within specific timeframes after the application is accepted for filing. The Attorney General must register the applicant within specific timeframes after the application is accepted for filing. Additionally, re-exportation among members of the European Economic Area is allowed under certain conditions. Re-exportation among members of the European Economic Area is allowed under specific conditions, including meeting certain requirements for each subsequent country involved in the export process. Re-exportation among members of the European Economic Area requires documentation certifying each re-exportation within 30 days, including information on the consignee, country, and product. The Attorney General is limited in promulgating regulations for controlled substances in certain schedules. The Attorney General is limited in promulgating regulations for controlled substances in certain schedules, specifically regarding re-exportation among European Economic Area countries. This includes not enforcing requirements for specific timeframes or information provision before exportation. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}